RESUMO
OBJECTIVES: The introduction of low-dose CT (LDCT) altered the landscape of lung cancer (LC) screening and contributed to the reduction of mortality rates worldwide. Here we report the final results of HUNCHEST-II, the largest population-based LDCT screening program in Hungary, including the screening and diagnostic outcomes, and the characteristics of the LC cases. METHODS: A total of 4215 high-risk individuals aged between 50 and 75 years with a smoking history of at least 25 pack-years were assigned to undergo LDCT screening. Screening outcomes were determined based on the volume, growth, and volume doubling time of pulmonary nodules or masses. The clinical stage distribution of screen-detected cancers was compared with two independent practice-based databases consisting of unscreened LC patients. RESULTS: The percentage of negative and indeterminate tests at baseline were 74.2% and 21.7%, respectively, whereas the prevalence of positive LDCT results was 4.1%. Overall, 76 LC patients were diagnosed throughout the screening rounds (1.8% of total participants), out of which 62 (1.5%) patients were already identified in the first screening round. The overall positive predictive value of a positive test was 58%. Most screen-detected malignancies were stage I LCs (60.7%), and only 16.4% of all cases could be classified as stage IV disease. The percentage of early-stage malignancies was significantly higher among HUNCHEST-II screen-detected individuals than among the LC patients in the National Koranyi Institute of Pulmonology's archive or the Hungarian Cancer Registry (p < 0.001). CONCLUSIONS: HUNCHEST-II demonstrates that LDCT screening for LC facilitates early diagnosis, thus arguing in favor of introducing systematic LC screening in Hungary. CLINICAL RELEVANCE STATEMENT: HUNCHEST-II is the so-far largest population-based low-dose CT screening program in Hungary. A positive test's overall positive predictive value was 58%, and most screen-detected malignancies were early-stage lesions. These results pave the way for expansive systematic screening in the region. KEY POINTS: ⢠Conducted in 18 medical facilities, HUNCHEST-II is the so far largest population-based low-dose CT screening program in Hungary. ⢠The vast majority of screen-detected malignancies were early-stage lung cancers, and the overall positive predictive value of a positive test was 58%. ⢠HUNCHEST-II facilitates early diagnosis, thus arguing in favor of introducing systematic lung cancer screening in Hungary.
RESUMO
BACKGROUND: The Hungarian Health Insurance Fund, using appropriate information technology, covers all of the secondary care of the country and maintains a database of Hospital Discharge Records (HDR). Our study aimed to determine the incidence, average age-at-diagnosis (AaD), and prevalence of myasthenia gravis (MG) among adults and the regional heterogeneity of these measures to assess the potential usefulness of HDRs for monitoring. METHODS: The nationwide database of 336,679 HDRs from 2004 to 2009 was analyzed. The incidence and prevalence were determined for adults in 2007. Patients with MG code in 2007, 2008, and 2009 but without that in 2004-2006 were defined as incident. Distribution of AaD was described for these cases. Patients with an MG code in 2007, 2008, and 2009 were defined as prevalent in 2007. The heterogeneity of regional age-standardized indices was tested. RESULTS: The observed incidence and prevalence was 2.76/100,000 (men: 2.37/100,000; women: 3.11/100,000) and 17.42/100,000 (male: 13.08/100,000; female: 21.28/100,000), respectively. These estimates were within published ranges. The mean AaD was significantly higher for men than for women (63.60 vs. 51.92; p < 0.001). Significant regional heterogeneity was observed for all measures. CONCLUSIONS: HDRs seem to be useful for developing MG indicators because they adequately estimate epidemiological parameters of MG occurrence.